Arvinas, Pfizer, Rigel close VEPPANU license deal; $70M upfront received

ARVINAS, INC.

HSR waiting period terminated June 11, 2026, making License Agreement effective.
Rigel paid $70M aggregate upfront to Arvinas and Pfizer, split evenly.
Additional $15M payable upon successful completion of transition activities.
Up to $320M in development, regulatory, and commercial milestones plus tiered royalties.
Milestones and royalties replace unearned payments from Pfizer to Arvinas under prior collaboration.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.